EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Discoveries and future significance of research into amyloid-beta/α7-containing nicotinic acetylcholine receptor (nAChR) interactions

Paul Whiteaker, Andrew A George

Pharmacological Research · 2023

DOI: 10.1016/j.phrs.2023.106743 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmacological Research, 2023. Verfasst von Paul Whiteaker und 1 weiteren Autor:innen. Beteiligte Einrichtung: Virginia Commonwealth University School of Medicine, Department of Pharmacology and Toxicology, VCU Health Sciences Research Building, Box 980613, Ri…. Hauptthemen laut MEDLINE: Receptors, Nicotinic, Alzheimer Disease. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 161 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDA NIH HHS, NIA NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Initiated by findings that Alzheimer's disease is associated with a profound loss of cholinergic markers in human brain, decades of studies have examined the interactions between specific subtypes of nicotinic acetylcholine receptors and amyloid-β [derived from the amyloid precursor protein (APP), which is cleaved to yield variable isoforms of amyloid-β]. We review the evolving understanding of amyloid-β's roles in Alzheimer's disease and pioneering studies that highlighted a role of nicotinic acetylcholine receptors in mediating important aspects of amyloid-β's effects. This review also surveys the current state of research into amyloid-β / nicotinic acetylcholine receptor interactions. The field has reached an exciting point in which common themes are emerging from the wide range of prior research and a range of accessible, relevant model systems are available to drive further progress. We highlight exciting new areas of inquiry and persistent challenges that need to be considered while conducting this research. Studies of amyloid-β and the nicotinic acetylcholine receptor populations that it interacts with provide opportunities for innovative basic and translational scientific breakthroughs related to nicotinic receptor biology, Alzheimer's disease, and cholinergic contributions to cognition more broadly.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, NicotinicAlzheimer DiseaseAnimalsHumansalpha7 Nicotinic Acetylcholine ReceptorAmyloid beta-PeptidesCholinergic AgentsDisease Models, Animal

Stichwörter der Autor:innen

Alzheimer’s diseaseCholinergic neuronsMemoryNeuronal hyperexcitationNicotinic receptorsOligomeric amyloid-beta

Substanzen

Receptors, Nicotinicalpha7 Nicotinic Acetylcholine ReceptorAmyloid beta-PeptidesCholinergic Agents

Autor:innen und Institutionen

  • Virginia Commonwealth University School of Medicine, Department of Pharmacology and Toxicology, VCU Health Sciences Research Building, Box 980613, Richmond, VA 23298-0613, USA.
  • Virginia Commonwealth University School of Medicine, Department of Pharmacology and Toxicology, VCU Health Sciences Research Building, Box 980613, Richmond, VA 23298-0613, USA. Electronic address: Andrew.George@vcuhealt…

Förderung

  • NIDA NIH HHS
  • NIA NIH HHS
  • National Institutes of Health

Zitieren

APA

Whiteaker, P., & George, A. A. (2023). Discoveries and future significance of research into amyloid-beta/α7-containing nicotinic acetylcholine receptor (nAChR) interactions. Pharmacological Research. https://doi.org/10.1016/j.phrs.2023.106743

Vancouver

Whiteaker P, George AA. Discoveries and future significance of research into amyloid-beta/α7-containing nicotinic acetylcholine receptor (nAChR) interactions. Pharmacological Research. 2023. doi:10.1016/j.phrs.2023.106743

BibTeX
@article{Whiteaker2023,
  author = {Whiteaker, Paul and George, Andrew A},
  title = {Discoveries and future significance of research into amyloid-beta/α7-containing nicotinic acetylcholine receptor (nAChR) interactions},
  journal = {Pharmacological Research},
  year = {2023},
  doi = {10.1016/j.phrs.2023.106743}
}
Kostenlos starten →